Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Process for the preparation of olmesartan medoxomil

A technology for olmesartan medoxomil and carboxylate is applied in the field of preparing olmesartan medoxomil, and can solve the problems of cumbersome process, reduced yield, removal of difficult pharmaceutical active compounds and the like

Inactive Publication Date: 2008-08-06
KRKA
View PDF4 Cites 24 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] The general disadvantages of the prior art methods present in the proposed method, besides the use of column chromatography, involve additional separation steps which are known to reduce the yield and make the process cumbersome
Also the use of certain solvents such as acetic acid in later reaction steps necessitates an additional crystallization / purification step since, especially acetic acid is known to potentially lead to the formation of permanent impurities during drying, when present as residual solvent, It is also difficult to remove from pharmaceutically active compounds

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for the preparation of olmesartan medoxomil
  • Process for the preparation of olmesartan medoxomil
  • Process for the preparation of olmesartan medoxomil

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0120] 17.3g (124.8mmol) potassium carbonate, 15g (62.4mmol) ethyl-4-(1-hydroxyl-1-methylethyl)-2-propylimidazole-5-carboxylate (III) and 38.3g ( 68.7 mmol) of 4-[2-(trityltetrazol-5-yl)phenyl]-benzyl bromide (IVa) was suspended in 750 ml of acetonitrile. The suspension was then heated under reflux until the reaction was complete (7 hours). 510ml of acetonitrile was distilled off, and the concentrate was cooled to 23-25°C. The mixture was stirred overnight at this temperature, then the suspension was cooled to 0°C and stirred at this temperature for 1 hour. The crude product (Va) was filtered off and washed 2x20ml with cold acetonitrile. The wet product was suspended in 450 ml of water, stirred for 1.5 hours, and filtered off. The mass of dry product (Va) was 39.5 g (89%).

[0121] T=165-169°C

[0122] IR: 1666, 1525, 1291, 1446, 1177, 881, 756, 669, 640

Embodiment 2

[0124] 36.0g (50.3mmol) ethyl-4-(1-hydroxyl-1-methylethyl)-2-propyl-1-{4-[2-(trityltetrazol-5-yl)benzene Base]phenyl}-methyl-imidazole-5-carboxylate (Va) and 3.0 g (75.4 mmol) of NaOH were suspended in 413 ml of dimethylacetamide. The suspension was then stirred at room temperature for 20 hours, and a further 6.9 g (50.3 mmol) of potassium carbonate were added. The mixture was cooled to 0°C, and slowly added in 39ml of dimethylacetamide containing 15.4g (70.4mmol) of 4-chloromethyl-5-methyl-2-oxo-1,3-dioxole The solution. The mixture was slowly heated to 50°C and stirred at this temperature for 2 hours. After the esterification was completed, the mixture was cooled to 10°C, poured into a mixture containing 625ml of ethyl acetate and 625ml of 10% NaCl, and stirred at 25°C for 15min. The liquid phases were separated and the organic phase was washed with 2x500ml 10% NaCl, dried over sodium sulfate and filtered. The filtrate was concentrated to 1 / 2 (about 270 g) under reduced ...

Embodiment 3

[0128] 1.11 g of olmesartan medoxomil was dissolved in 12.5 ml of 2-butanone under reflux conditions. The solution was slowly cooled to room temperature and stirred at this temperature for 20 hours. During this process, olmesartan medoxomil slowly crystallizes. The product was filtered and dried at room conditions for 18 hours. We obtain 0.98 g of olmesartan medoxomil.

[0129] The crystal form of the product was as described in Annual Report of Sankyo Research Laboratories Vol. 55 (2003).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to an improved process for the manufacture of olmesartan and pharmaceutically acceptable salts and esters thereof as an active ingredient of a medicament for the treatment of hypertension and related diseases and conditions.

Description

field of invention [0001] The present invention relates to an improved process for the production of olmesartan and its pharmaceutically acceptable salts and esters for use as active ingredients of medicaments for the treatment of hypertension and related diseases and conditions. [0002] technical problem [0003] In medicine, olmesartan medoxomil, chemically known as (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl-4-(1 -Hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate ((5 -methyl-2-oxo-1,3-dioxolen-4-yl)methyl-4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl) phenyl]phenyl}methylimidazole-5-carboxylate), is widely used in the treatment of hypertension and related diseases and conditions due to its ability to inhibit the angiotensin-covering enzyme. As an angiotensin II receptor antagonist (an angiotensin II receptor antagonist), olmesartan medoxomil eliminates the side effects of calcium ion antagonists, and shows high s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D405/14
Inventor 西尔沃・祖潘契奇阿妮察・佩卡瓦尔米哈・弗尔宾克雷娜塔・奥索尔尼克
Owner KRKA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com